BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21083252)

  • 1. Microdosing in early lead discovery.
    Jekunen AP; Pauwels EK; Kairemo KJ
    Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdosing: current and the future.
    Lappin G
    Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
    Oosterhuis B
    Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
    [No Abstract]   [Full Text] [Related]  

  • 5. Ethical, legal, and social implications (ELSI) of microdose clinical trials.
    Kurihara C
    Adv Drug Deliv Rev; 2011 Jun; 63(7):503-10. PubMed ID: 21251940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opinion: Microdosing: safer clinical trials and fewer animal tests.
    Langley G; Farnaud S
    Bioanalysis; 2010 Mar; 2(3):393-5. PubMed ID: 21083249
    [No Abstract]   [Full Text] [Related]  

  • 7. Welcome to 'microdosing'.
    Ings RM
    Bioanalysis; 2010 Mar; 2(3):371-2. PubMed ID: 21083244
    [No Abstract]   [Full Text] [Related]  

  • 8. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
    Salehpour M; Ekblom J; Sabetsky V; HÃ¥kansson K; Possnert G
    Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdosing: the new pharmacokinetic paradigm?
    Zanni GR; Wick JY
    Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
    Feng B; LaPerle JL; Chang G; Varma MV
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
    Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
    J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.